Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
REVIEW
Melanie M Liu, Andrea B Reidy, Siavosh Saatee, Charles D Collard
No abstract text is available yet for this article.
July 2017: Anesthesiology
#2
JOURNAL ARTICLE
Lee A Fleisher, Kirsten E Fleischmann, Andrew D Auerbach, Susan A Barnason, Joshua A Beckman, Biykem Bozkurt, Victor G Davila-Roman, Marie D Gerhard-Herman, Thomas A Holly, Garvan C Kane, Joseph E Marine, M Timothy Nelson, Crystal C Spencer, Annemarie Thompson, Henry H Ting, Barry F Uretsky, Duminda N Wijeysundera
No abstract text is available yet for this article.
December 9, 2014: Journal of the American College of Cardiology
#3
COMPARATIVE STUDY
Pavel S Roshanov, Bram Rochwerg, Ameen Patel, Omid Salehian, Emmanuelle Duceppe, Emilie P Belley-Côté, Gordon H Guyatt, Daniel I Sessler, Yannick Le Manach, Flavia K Borges, Vikas Tandon, Andrew Worster, Alexandra Thompson, Mithin Koshy, Breagh Devereaux, Frederick A Spencer, Robert D Sanders, Erin N Sloan, Erin E Morley, James Paul, Karen E Raymer, Zubin Punthakee, P J Devereaux
BACKGROUND: The effect on cardiovascular outcomes of withholding angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers in chronic users before noncardiac surgery is unknown. METHODS: In this international prospective cohort study, the authors analyzed data from 14,687 patients (including 4,802 angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker users) at least 45 yr old who had in-patient noncardiac surgery from 2007 to 2011...
January 2017: Anesthesiology
#4
RANDOMIZED CONTROLLED TRIAL
James D Douketis, Alex C Spyropoulos, Scott Kaatz, Richard C Becker, Joseph A Caprini, Andrew S Dunn, David A Garcia, Alan Jacobson, Amir K Jaffer, David F Kong, Sam Schulman, Alexander G G Turpie, Vic Hasselblad, Thomas L Ortel
BACKGROUND: It is uncertain whether bridging anticoagulation is necessary for patients with atrial fibrillation who need an interruption in warfarin treatment for an elective operation or other elective invasive procedure. We hypothesized that forgoing bridging anticoagulation would be noninferior to bridging with low-molecular-weight heparin for the prevention of perioperative arterial thromboembolism and would be superior to bridging with respect to major bleeding. METHODS: We performed a randomized, double-blind, placebo-controlled trial in which, after perioperative interruption of warfarin therapy, patients were randomly assigned to receive bridging anticoagulation therapy with low-molecular-weight heparin (100 IU of dalteparin per kilogram of body weight) or matching placebo administered subcutaneously twice daily, from 3 days before the procedure until 24 hours before the procedure and then for 5 to 10 days after the procedure...
August 27, 2015: New England Journal of Medicine
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
